Ovid Therapeutics Inc. (OVID)


+0.11 (+2.90%)
Symbol OVID
Price $3.9
Beta 1.132
Volume Avg. 0.17M
Market Cap 275.351M
Shares () -
52 Week Range 1.405-4.139
1y Target Est -
DCF Unlevered OVID DCF ->
DCF Levered OVID LDCF ->
ROE 1176.15% Strong Buy
ROA 1092.09% Strong Buy
Operating Margin -
Debt / Equity 14.76% Neutral
P/E -5.42 Strong Sell
P/B 2.48 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest OVID news

Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir
NASDAQ Global Select

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.